...
首页> 外文期刊>Nucleic Acids Research >Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis
【24h】

Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis

机译:Vegfr-2启动子中G-四链体及其靶向抑制肿瘤血管生成的证据

获取原文
获取原文并翻译 | 示例
           

摘要

Tumor angiogenesis is mainly mediated by vascular endothelial growth factor (VEGF), a pro-angiogenic factor produced by cancer cells and active on the endothelium through the VEGF receptor 2 (VEGFR-2). Here we identify a G-rich sequence within the proximal promoter region of vegfr-2, able to form an antiparallel G-quadruplex (G4) structure. This G4 structure can be efficiently stabilized by small molecules with the consequent inhibition of vegfr-2 expression. Functionally, the G4-mediated reduction of VEGFR-2 protein causes a switching off of signaling components that, converging on actin cytoskeleton, regulate the cellular events leading to endothelial cell proliferation, migration and differentiation. As a result of endothelial cell function impairment, angiogenic process is strongly inhibited by G4 ligands both in vitro and in vivo. Interestingly, the G4-mediated antiangiogenic effect seems to recapitulate that observed by using a specific interference RNA against vegfr-2, and it is strongly antagonized by overexpressing the vegfr-2 gene. In conclusion, we describe the evidence for the existence of G4 in the promoter of vegfr-2, whose expression and function can be markedly inhibited by G4 ligands, thereby revealing a new, and so far undescribed, way to block VEGFR-2 as target for anticancer therapy.
机译:肿瘤血管生成主要由血管内皮生长因子(VEGF)介导,血管内皮生长因子是癌细胞产生的促血管生成因子,并通过VEGF受体2(VEGFR-2)在内皮上具有活性。在这里,我们确定vegfr-2的近端启动子区域内的富含G的序列,能够形成反平行的G-四链体(G4)结构。小分子可以有效地稳定该G4结构,从而抑制vegfr-2的表达。从功能上讲,G4介导的VEGFR-2蛋白的减少导致信号转导元件的关闭,这些信号转导聚集在肌动蛋白细胞骨架上,调节细胞事件,导致内皮细胞增殖,迁移和分化。由于内皮细胞功能受损,在体外和体内,血管生成过程均受到G4配体的强烈抑制。有趣的是,G4介导的抗血管生成作用似乎可以概括通过使用针对vegfr-2的特异性干扰RNA所观察到的效果,并且它通过过表达vegfr-2基因而被强烈拮抗。总之,我们描述了vegfr-2启动子中存在G4的证据,其表达和功能可被G4配体显着抑制,从而揭示了一种新的,至今未描述的阻断VEGFR-2作为靶标的方法。用于抗癌治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号